Pages that link to "Q38670109"
Jump to navigation
Jump to search
The following pages link to Seventeen years of statin pharmacogenetics: a systematic review (Q38670109):
Displaying 14 items.
- Pharmacogenomics of statins: understanding susceptibility to adverse effects (Q28079822) (← links)
- Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin (Q33648028) (← links)
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins (Q34680467) (← links)
- Personalized medicine: Genetic risk prediction of drug response (Q38756015) (← links)
- Do Statins Have Antidepressant Effects? (Q39183235) (← links)
- More than 25 years of genetic studies of clozapine-induced agranulocytosis. (Q39247893) (← links)
- Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity (Q41526681) (← links)
- Systems Pharmacology Dissection of Cholesterol Regulation Reveals Determinants of Large Pharmacodynamic Variability between Cell Lines (Q47262709) (← links)
- Effect of genetic polymorphisms in SREBF-SCAP pathway on therapeutic response to rosuvastatin in Saudi metabolic syndrome patients. (Q50108375) (← links)
- Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome (Q51304354) (← links)
- Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review (Q57490969) (← links)
- Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease (Q88868156) (← links)
- CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer (Q90169812) (← links)
- Genetic contribution to lipid target achievement with statin therapy: a prospective study (Q91736525) (← links)